<DOC>
	<DOC>NCT01997892</DOC>
	<brief_summary>To describe the time course of hemoglobin concentration in EU hemodialysis patients switched from methoxy polyethylene glycol-epoetin beta (PEG epoetin beta; Mircera) to darbepoetin alfa (Aranesp).</brief_summary>
	<brief_title>TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta</brief_title>
	<detailed_description>This is a multi-centre, observational cohort study of EU hemodialysis patients whose erythropoiesis stimulating agent (ESA) therapy has been switched from PEG epoetin beta to darbepoetin alfa. Data will be collected for the period spanning 14 weeks prior to switch through to 26 weeks post-switch.</detailed_description>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients &gt;18 years of age. CKD diagnosis, receiving hemodialysis Received PEG epoetin beta for 14weeks prior to switching to darbepoetin alfa and received at least one dose of darbepoetin alfa.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>CKD</keyword>
	<keyword>Darbepoetin Alfa</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Anemia</keyword>
	<keyword>Peg epoetin beta</keyword>
</DOC>